<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Internal Medicine: Medical Ethics Topic Collection</title>
    <link>http://archinte.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 22 Apr 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Mon, 22 Apr 2013 15:46:58 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archinte.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archinte.jamanetwork.com</webMaster>
    <item>
      <title>Improving Health With Partnerships Between Academia and Industry Partnerships Between Academia and Industry </title>
      <link>http://archinte.jamanetwork.com/article.aspx?articleID=1680144</link>
      <pubDate>Mon, 22 Apr 2013 00:00:00 GMT</pubDate>
      <author>Desmond-Hellmann S. </author>
      <description>&lt;span class="paragraphSection"&gt;At a time when jobs seem scarce, one role seems to have multiplied: the pundit; never at a loss for a provocative, deeply held view or opinion. And, one of the rapidly expanding punditry themes is focused on the purported “evils” of the pharmaceutical industry and the potential for an associated corrupting influence of money on innovation in health. In his new book, Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients, Ben Goldacre, BA, MBBS, MA, MRCPsych, a British physician and writer, says&lt;/span&gt;</description>
      <prism:startingPage xmlns:prism="prism">1</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">2</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamainternmed.2013.826</prism:doi>
      <guid>http://archinte.jamanetwork.com/article.aspx?articleID=1680144</guid>
    </item>
  </channel>
</rss>